logo-loader
HealthPharma & Biotech
AstraZeneca

Still some downside at AstraZeneca says Zak Mir

Trump may have adopted rival's drug plans

AstraZeneca PLC (LON:AZN) shares have fallen recently with the sector on the back of fears US drugs may be made cheaper by new chairman Donald Trump.

The new president has seemingly stolen a policy from his presidential rival Hillary Clinton, says Zak Mir, Tip TV’s technical analyst.

Astra has very important cancer drug trials underway with results due next year.

The price chart shows falls in October and November and with the main support level at £38 there may be a couple of pounds more on the downside before bargain hunters appear says Mir.

Quick facts: AstraZeneca

Price: £71.27

Market: LSE
Market Cap: £93.5 billion
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

hVIVO PLC's 2020 pipeline 'looking strong' as it expands service offerings

hVIVO PLC's (LON:HVO) executive chairman Trevor Phillips tells Proactive London's Andrew Scott the business is now better positioned to be profitable next year. The creator of pioneering human disease models based upon viral challenge generated revenues of £5.9mln in the six months ended June...

12 hours, 12 minutes ago

2 min read

;